Dr. Christopher Earl Pelt, MD

Dr. Pelt practices at University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah.

Dr. Pelt's NPI, 1073653036, was assigned on February 7, 2007. Dr. Pelt graduated from Creighton University School of Medicine in 2005. Dr. Pelt holds Utah license 6353402-1205.

Dr. Pelt's primary practice is University of Utah Hospitals and Clinics - Unit, at 50 North Medical Drive, Salt Lake City, UT 84132 in Salt Lake County. The practice phone is (801) 581-2337.

Dr. Pelt's primary practice is University of Utah Hospitals and Clinics - Unit in Salt Lake City, Utah. Dr. Pelt is also affiliated with University of Utah Hospital. The medical group on file is University of Utah Health. Dmand AI also links Dr. Pelt to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Pelt practices, 5 sites in all. Vendor and product names are available with a free account.

Orthopaedic surgery is Dr. Pelt's primary specialty in the NPI Registry, under taxonomy code 207X00000X. Dr. Pelt is board certified in orthopaedic surgery by the American Board of Orthopaedic Surgery. Dr. Pelt is licensed in Utah.

CMS data shows 670 Medicare services from Dr. Pelt across 11 procedure codes in 2024, for 326 Medicare patients. Medicare paid $163,500 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 326 Medicare patients who saw Dr. Pelt in 2024. The largest group is 65 to 74, with 178 patients. 75% of them have arthritis, and 70% have high blood pressure. 7% are also on Medicaid. Their average risk score is 1.05, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Pelt's median patient age at 72, with 56% women.

In 2024, Dr. Pelt wrote 119 Medicare Part D claims for 46 patients. 87% of them were for generic drugs. CMS names the drug for 56 of them, across 4 drugs with 11 or more claims each, at $1,043 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Pelt for performance year 2024, reported as part of a group. Dr. Pelt accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Pelt as offering telehealth. CMS counts 87 procedures of knee replacement by Dr. Pelt, more than 91% of the clinicians it reports for that procedure.

Dmand AI links 131 papers to Dr. Pelt, published from 2011 to 2025. 2018 was the busiest year, with 14. The most frequent topics are Arthroplasty, Replacement, Knee, Arthroplasty, Replacement, Hip and Reoperation. Dr. Pelt has published most often in J Arthroplasty. Dr. Pelt's most frequent co-authors are Christopher L. Peters, MD, Michael J. Archibeck, MD and Ryland Kagan, MD.

Dmand AI links Dr. Pelt to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Osteoarthritis, Hip, Hip Fractures and Bronchiolitis Obliterans Syndrome. Zimmer Biomet sponsors the most, 2.

CMS Open Payments shows 366 general payments to Dr. Pelt from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 52% of the total. Total Joint Orthopedics, Inc. paid the most, $287,158. It also lists 3 research payments totaling $23,699 from 2024 to 2025.

Dr. Pelt graduated from Creighton University School of Medicine in 2005.